Greece Obesity Treatment Program Faces Funding Uncertainty
Around 46,000 participants in Greece’s free obesity treatment programme face a possible interruption as authorities seek emergency funding to extend care until a planned restart in September.
Read the full articleYou might also wanna read
Medicine can treat obesity, but can’t agree on what obesity is
Declaring it always a disease means millions will get treatment they may not need, writes Francesco Rubino
Medicare begins covering weight-loss medications: who qualifies and how the new program will work
A pilot program will, for the first time, allow millions of beneficiaries to access GLP-1 medications to treat obesity with a monthly copay
Obesity Is Fueling Britain’s Growing Health and Long-Term Care Crisis
Obesity is becoming one of the biggest drivers of chronic illness, disability, NHS spending, and long-term care demand as the population age
How many Canadian employers are offering GLP-1 coverage for weight loss?
Cost control, eligibility requirements, and health risks of obesity among key factors shaping employer approach to medication: IFEBP survey
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Conditions : Overweight or Obesity Interventions : Drug: Olatorepatide; Drug: Placebo Sponsors : Regeneron Pharmaceuticals Not yet recruitin
More Americans Than Ever Are Taking Weight-Loss Drugs
The number of U.S. adults taking an obesity medication has nearly quadrupled from just two years ago.
Comments
Sign in to join the conversation.
No comments yet. Be the first.